Tateishi T - Search Results

1

Effect of dietary fat content in meals on pharmacokinetics of quazepam.

Yasui-Furukori N, Kondo T, Takahata T, Mihara K, Ono S, Kaneko S, Tateishi T. Yasui-Furukori N, et al. Among authors: tateishi t. J Clin Pharmacol. 2002 Dec;42(12):1335-40. doi: 10.1177/0091270002042012004. J Clin Pharmacol. 2002. PMID: 12463728 Clinical Trial.

2

Carbamazepine decreases antihypertensive effect of nilvadipine.

Yasui-Furukori N, Tateishi T. Yasui-Furukori N, et al. Among authors: tateishi t. J Clin Pharmacol. 2002 Jan;42(1):100-3. doi: 10.1177/0091270002042001012. J Clin Pharmacol. 2002. PMID: 11808819

3

Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia.

Yasui-Furukori N, Mihara K, Kondo T, Kubota T, Iga T, Takarada Y, De Vries R, Kaneko S, Tateishi T. Yasui-Furukori N, et al. Among authors: tateishi t. J Clin Pharmacol. 2003 Feb;43(2):122-7. doi: 10.1177/0091270002239819. J Clin Pharmacol. 2003. PMID: 12616663

4

Time effects of food intake on the pharmacokinetics and pharmacodynamics of quazepam.

Yasui-Furukori N, Takahata T, Kondo T, Mihara K, Kaneko S, Tateishi T. Yasui-Furukori N, et al. Among authors: tateishi t. Br J Clin Pharmacol. 2003 Apr;55(4):382-8. doi: 10.1046/j.1365-2125.2003.01775.x. Br J Clin Pharmacol. 2003. PMID: 12680887 Free PMC article. Clinical Trial.

5

Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes.

Yasui-Furukori N, Takahata T, Nakagami T, Yoshiya G, Inoue Y, Kaneko S, Tateishi T. Yasui-Furukori N, et al. Among authors: tateishi t. Br J Clin Pharmacol. 2004 Apr;57(4):487-94. doi: 10.1111/j.1365-2125.2003.02047.x. Br J Clin Pharmacol. 2004. PMID: 15025747 Free PMC article. Clinical Trial.

6

Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes.

Yasui-Furukori N, Mihara K, Takahata T, Suzuki A, Nakagami T, De Vries R, Tateishi T, Kondo T, Kaneko S. Yasui-Furukori N, et al. Among authors: tateishi t. Br J Clin Pharmacol. 2004 May;57(5):569-75. doi: 10.1111/j.1365-2125.2003.02061.x. Br J Clin Pharmacol. 2004. PMID: 15089809 Free PMC article.

7

The effects of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of donepezil.

Yasui-Furukori N, Furukori H, Kaneda A, Kaneko S, Tateishi T. Yasui-Furukori N, et al. Among authors: tateishi t. J Clin Pharmacol. 2004 May;44(5):538-42. doi: 10.1177/0091270004264161. J Clin Pharmacol. 2004. PMID: 15102875

8

Fexofenadine does not affect omeprazole pharmacokinetics: both are putative P-glycoprotein substrates.

Takahata T, Yasui-Furukori N, Yoshiya G, Uno T, Sugawara K, Tateishi T. Takahata T, et al. Among authors: tateishi t. Basic Clin Pharmacol Toxicol. 2004 May;94(5):252-6. doi: 10.1111/j.1742-7843.2004.pto940509.x. Basic Clin Pharmacol Toxicol. 2004. PMID: 15125696 Free article.

9

Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes.

Yasui-Furukori N, Saito M, Uno T, Takahata T, Sugawara K, Tateishi T. Yasui-Furukori N, et al. Among authors: tateishi t. J Clin Pharmacol. 2004 Nov;44(11):1223-9. doi: 10.1177/0091270004269015. J Clin Pharmacol. 2004. PMID: 15496639 Clinical Trial.

10

Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics.

Yasui-Furukori N, Uno T, Sugawara K, Tateishi T. Yasui-Furukori N, et al. Among authors: tateishi t. Clin Pharmacol Ther. 2005 Jan;77(1):17-23. doi: 10.1016/j.clpt.2004.08.026. Clin Pharmacol Ther. 2005. PMID: 15637527 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

472 results

Search Page

Filters